Risk of Ovarian Cancer Relapse Score

Ivana Rizzuto(Imperial College Healthcare NHS Trust), Sarah P. Blagden(Churchill Hospital), Hani Gabra(Royal Children's Hospital), Jayanta Chatterjee(Imperial College Healthcare NHS Trust), Sadaf Ghaem‐Maghami(Hammersmith Hospital), Thomas G. Hopkins(Ovarian Cancer Action), Chara Stavraka(King's College London), Les Huson(Hammersmith Hospital), Jane Borley(Imperial College Healthcare NHS Trust)
International Journal of Gynecological Cancer
February 3, 2015
10.1097/igc.0000000000000361
Cited by 52

Related Papers

Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
|The Lancet|2019|223
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222